V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015800 | 160013105 | 1.01 | 38 | Curative (C) | 2016-12-13 | 2017-01-19 | Niraparib | Y | N | NIRAPARIB | 101350380 |
| 160015806 | 160013106 | 1.74 | 93.9 | null | 2017-05-30 | 2018-04-14 | CONFIRM TRIAL | 02 | null | TRIAL | 100832487 |
| 160015807 | 160013107 | 1.79 | 67.6 | Curative (C) | 2019-09-23 | 2019-10-13 | BEP 5 Day | 02 | null | PROMISE-MESO TRIAL | 100864853 |
| 160015809 | 160013108 | null | 67.6 | 03 | 2020-03-26 | 2020-03-28 | STS Rhabdo VIT0910 Vinc Irino Temoz | null | null | GEMCITABINE | 100276551 |
| 160015810 | 160013109 | 0 | 102 | Curative (C) | 2017-01-24 | 2017-02-02 | null | 02 | null | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 101421285 |
| 160015816 | 160013110 | 1.64 | 57 | 02 | 2016-03-11 | 2016-03-11 | Temozolomide 150mg/m2 | 02 | N | MELPHALAN | 101630734 |
| 160015817 | 160013111 | 1.86 | 12.3 | Neo-adjuvant (N) | 2019-03-11 | 2019-03-12 | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 02 | N | CISPLATIN + PACLITAXEL | 100532897 |
| 160015819 | 160013112 | 1.51 | 75.4 | null | 2019-03-10 | 2019-05-27 | Doxorubicin + Ifosfamide | 02 | null | IVADO | 100581305 |
| 160015823 | 160013115 | 1.65 | 16.5 | Palliative (P) | 2018-03-16 | 2018-08-16 | EW EuroEwing 2012 Arm B IE | N | N | ICON8B TRIAL | 100558380 |
| 160015825 | 160013116 | 0 | 68 | 03 | 2018-11-03 | 2018-11-10 | Ifosfamide | 02 | N | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 101615395 |
| 160015827 | 160013117 | 0 | 84.4 | null | 2019-03-17 | 2019-08-06 | STS Rhabdo RMS 2005 Vin Cyclo | null | null | IFOSFAMIDE | 100738285 |
| 160015828 | 160013118 | 0 | 73.2 | Curative (C) | 2019-02-17 | 2019-02-26 | EW EuroEwing 2012 Arm B IE | 02 | null | CISPLATIN + IFOSFAMIDE + PACLITAXEL | 101299042 |
| 160015829 | 160013119 | 1.59 | 12.4 | Palliative (P) | 2016-12-01 | 2016-12-11 | null | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100658904 |
| 160015831 | 160013120 | 0 | 77.3 | null | 2016-10-26 | 2017-02-22 | NB Low/Intermed risk guidelines CADO | 02 | null | NOT MATCHED | 100041074 |
| 160015832 | 160013121 | 1.69 | 66 | Curative (C) | 2019-07-14 | 2019-07-15 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101427803 |
| 160015833 | 160013122 | 0 | 55.1 | null | 2019-07-12 | 2019-07-14 | GC Int Guide Excranial GrmCell VeIP | 02 | null | PEMBROLIZUMAB | 100956787 |
| 160015836 | 160013123 | 1.61 | 59.1 | Neo-adjuvant (N) | 2017-07-23 | 2017-07-30 | null | 02 | N | CONFIRM TRIAL | 101478925 |
| 160015842 | 160013124 | null | null | Adjuvant (A) | 2019-11-14 | 2019-11-14 | EW EuroEwing 2012 Arm A VAI | 01 | N | TRASTUZUMAB | 100140786 |
| 160015844 | 160013125 | 1.68 | 101.9 | Palliative (P) | 2019-09-03 | 2019-09-24 | Olaparib | 02 | N | CONFIRM TRIAL | 101304292 |
| 160015847 | 160013126 | 1.56 | null | Curative (C) | 2016-06-15 | 2016-09-06 | Gem-Dex | 02 | null | IFOSFAMIDE | 101745278 |
| 160015848 | 160013127 | 1.75 | 80 | Palliative (P) | 2017-07-21 | 2017-07-22 | STS Rhabdomyosarcoma RMS 2005 IVADo | N | N | CONFIRM TRIAL | 101437570 |
| 160015849 | 160013128 | null | 72 | Curative (C) | null | 2019-08-02 | null | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101610665 |
| 160015851 | 160013129 | 1.45 | 60 | null | 2018-02-17 | 2018-03-10 | ETOPOSIDE + IFOSFAMIDE | 02 | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 101470115 |
| 160015854 | 160013130 | 0 | 58 | Palliative (P) | 2020-07-20 | 2020-07-21 | PEMBROLIZUMAB | 01 | N | STS NON-RHABDO EPSSG 2005 IVA | 100288806 |
| 160015857 | 160013131 | 0 | 58.2 | null | 2017-10-31 | 2018-09-09 | STS Rhabdomyosarcoma RMS 2005 IVA | N | null | CAPECITABINE | 101479949 |
| 160015859 | 160013132 | 1.71 | 13.3 | null | 2015-07-05 | 2016-04-13 | GEMCITABINE | 02 | null | TRIAL | 100282020 |
| 160015864 | 160013133 | 1.93 | 18 | null | 2021-05-09 | 2021-07-12 | EW EuroEwing 2012 Arm A/B Zol Acid | 02 | null | GEMCITABINE | 100802175 |
| 160015866 | 160013134 | 0 | 63.9 | null | 2020-08-03 | 2020-10-30 | GEMCITABINE | 02 | null | CISPLATIN + ETOPOSIDE | 101677649 |
| 160015868 | 160013135 | null | null | null | 2016-07-04 | 2016-07-12 | PEMBROLIZUMAB | null | null | CABOZANTINIB | 101234707 |
| 160015875 | 160013136 | 1.79 | 53.7 | Curative (C) | 2018-02-28 | 2020-07-25 | EW EuroEwing 99 : VActC | 02 | null | OLARATUMAB | 100721031 |
| 160015886 | 160013138 | 1.5 | 14.8 | Palliative (P) | 2021-07-02 | 2021-07-03 | EW EuroEwing 2012 Arm A VAI | N | N | NOT MATCHED | 100362817 |
| 160015888 | 160013139 | 1.61 | 63.25 | Neo-adjuvant (N) | 2017-04-26 | 2017-08-20 | Cyclophosphamide High Dose | 01 | N | EW EUROEWING 2012 ARM A VAC | 101320242 |
| 160015890 | 160013140 | 1.67 | 80.9 | Neo-adjuvant (N) | 2018-10-31 | 2019-02-04 | CAPECITABINE + OXALIPLATIN | 02 | N | ABIRATERONE | 100523382 |
| 160015893 | 160013141 | 1.6 | 2.3 | Neo-adjuvant (N) | 2019-07-31 | 2019-08-10 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | CONFIRM TRIAL | 101637409 |
| 160015898 | 160013143 | 1.72 | 78.4 | Palliative (P) | 2017-04-05 | 2017-12-17 | EW EuroEwing 2012 Arm B VC | 02 | N | IPILIMUMAB + NIVOLUMAB | 100851443 |
| 160015899 | 160013144 | null | 14.8 | null | 2021-10-02 | 2021-10-06 | Bevacizumab + CARBOPLATIN + PACLITAXEL | null | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100653734 |
| 160015900 | 160013145 | 1.78 | 75.7 | Palliative (P) | 2016-12-07 | 2016-12-12 | Capecitabine | 02 | N | IRINOTECAN + CISPLATIN + MITOMYCIN | 101625754 |
| 160015901 | 160013146 | 0 | 11.8 | Adjuvant (A) | 2020-09-08 | 2021-02-24 | NB HRNBL-1 Isotretinoin | 02 | null | EW EUROEWING 2012 ARM B VDC | 100329081 |
| 160015906 | 160013147 | null | 48.9 | Palliative (P) | 2017-05-18 | 2018-10-15 | null | 02 | N | FLUOROURACIL + IRINOTECAN | 100119747 |
| 160015916 | 160013148 | 1.66 | 79 | Palliative (P) | 2017-04-10 | 2017-07-06 | Olaratumab | 02 | N | NB HRNBL-1 BUMEL MAT | 101853045 |
| 160015932 | 160013151 | 1.66 | 81.65 | Palliative (P) | 2018-02-05 | 2018-02-13 | null | 02 | N | TOPOTECAN | 101462945 |
| 160015939 | 160013152 | 1.52 | null | Neo-adjuvant (N) | 2017-08-11 | 2017-09-07 | NB HRNBL-1 Isotretinoin | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100548305 |
| 160015943 | 160013153 | 1.61 | 11.9 | Curative (C) | 2021-03-07 | 2021-03-07 | Rucaparib | 02 | null | CAPECITABINE + OXALIPLATIN | 101679938 |
| 160015945 | 160013154 | 0 | 80.1 | Curative (C) | 2016-01-06 | 2016-10-26 | Cyclophosphamide PO +Vinorelbine IV | 02 | N | GEMCITABINE | 100565318 |
| 160015947 | 160013155 | 0 | 118.6 | null | 2017-09-11 | 2017-09-17 | CARBOPLATIN + VINORELBINE | 02 | null | PEMBROLIZUMAB | 100407842 |
| 160015951 | 160013156 | 0 | 47 | Adjuvant (A) | 2021-01-29 | 2021-01-30 | PEMBROLIZUMAB | 02 | N | EW EUROEWING 2012 ARM B IE | 100041219 |
| 160015952 | 160013157 | 1.86 | 19.3 | null | 2017-04-27 | 2018-04-22 | Doxorubicin + Ifosfamide | 02 | null | TRIAL | 100137761 |
| 160015953 | 160013158 | 1.77 | 17.9 | Palliative (P) | 2016-07-12 | 2016-07-13 | Bevacizumab+Carbo+Pacliaxel | 02 | N | IVA | 100409884 |
| 160015962 | 160013160 | 1.59 | 28.3 | null | null | 2016-10-16 | EW EuroEwing 2012 Arm A VAC | 02 | null | GEMCITABINE | 100350379 |
| 160015963 | 160013161 | 1.62 | 13.2 | null | 2020-11-27 | 2021-03-28 | Ifosfamide | null | null | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | 100797334 |